Welcome to our dedicated page for AGIOS PHARMACEUTICALS SEC filings (Ticker: AGIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Agios Pharmaceuticals, Inc. filings document the regulatory record of a Delaware, Nasdaq-listed commercial-stage biopharmaceutical company focused on rare diseases and hematology. Its 8-K reports furnish operating results, product revenue updates for PYRUKYND® and AQVESME™, business highlights, investor presentations, and Regulation FD disclosures tied to mitapivat commercialization, clinical programs, and regulatory interactions.
Proxy and current-report filings cover annual-meeting proposals, director elections, board-class structure, committee assignments, stockholder voting matters, and compensatory arrangements for directors. Other disclosures address board appointments, pharmacovigilance communications involving PYRUKYND, exhibit filings, and Inline XBRL cover-page data.
AGIO reported Form 144 sale/transfer activity tied to executive restricted stock units. The filing lists 19,068 shares associated with vesting of RSUs on 04/02/2026 and discloses a prior sale of 18,055 shares on 03/02/2026 for $522,873.
AGIO submitted a Form 144 notice to sell 3,141 shares of Common Stock tied to the vesting of Restricted Stock Units on 04/02/2026. The excerpt also shows a prior sale by Cecilia Jones of 5,035 shares on 03/02/2026.
AGIO Therapeutics reported a notice under Rule 144 for common stock related to an insider transaction. The filing shows 2,959 shares tied to the vesting of Restricted Stock Units on 04/02/2026. The filing also records that Krishnan Viswanadhan had 2,959 shares listed under "Securities Sold During The Past 3 Months" with an associated dollar figure of $82,260.00 dated 03/05/2026.
AGIO affiliate filed a Form 144 notice for proposed sales of Common Stock tied to the vesting of restricted stock units on 04/02/2026. The filing lists quantities and dollar values for recent sales by Tsveta Milanova, including 2,868 shares ($83,057.00) on 03/02/2026 and 2,872 shares ($77,601.00) on 01/05/2026.
AGIO Pharmaceuticals reported a proposed sale of 2,940 shares of Common Stock under a Form 144 notice dated 04/02/2026, arising from the vesting of Restricted Stock Units. The filing also reports a prior sale of 4,055 shares on 03/02/2026.
The Form 144 lists the broker Morgan Stanley Smith Barney LLC and shows monetary figures adjacent to the share entries. The filing documents a routine affiliate sale notice tied to RSU vesting.
AGIO filed a Form 144 reporting the vesting of 3,280 restricted stock units on 04/02/2026. The filing also records a prior sale of 5,218 shares by James Burns on 03/02/2026, shown under "Securities Sold During The Past 3 Months."
The Vanguard Group filed Amendment No. 10 to Schedule 13G/A reporting zero beneficial ownership of Agios Pharmaceuticals Inc. common stock as of 03/13/2026. The filing explains an internal realignment effective January 12, 2026, that disaggregated beneficial ownership among Vanguard subsidiaries.
Agios Pharmaceuticals executive Krishnan Viswanadhan, Chief Corp Dev & Strategy, reported several equity transactions on March 5, 2026 tied to restricted stock units (RSUs). He exercised 8,100 RSUs, converting them into 8,100 shares of common stock at a price of $0.00 per share, reflecting the nature of RSUs as equity awards rather than open-market purchases. Following this, 2,959 common shares were sold at $27.80 per share to cover tax withholding obligations related to the RSU vesting, under durable automatic sale instructions consistent with Rule 10b5-1(c). After these transactions, he directly held 16,200 RSUs and 5,141 common shares. The RSUs were granted on March 5, 2025, with the underlying shares scheduled to vest in three equal annual installments beginning March 5, 2026.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Form 144 reporting a proposed resale related to the vesting of 2,959 Restricted Stock Units into Common Stock. The vesting and proposed sale date is 03/05/2026, and the shares are listed on Nasdaq.
AGIOS PHARMACEUTICALS, INC. reported that Principal Accounting Officer Theodore James Washburn Jr. completed an open-market sale of common stock. On March 3, 2026, he sold 5,272 shares at a price of $28.88 per share and held 868 shares of common stock afterward.